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Background: Patients receiving first-line afatinib, gefitinib or erlotinib for epidermal
growth factor receptor (EGFR) mutant advanced non-small cell lung cancer develop
progression of disease (PD) after an average of 9-13 months.
Methods: A retrospective analysis of PD pattern and prevalence of acquired T790M
mutation among patients failing first-line afatinib versus gefitinib or erlotinib at
University Malaya Medical Centre from 1st January 2015 to 31th December 2018.
Results: Of 87 patients who developed PD while on first-line EGFR-tyrosine kinase
inhibitor (TKI) treatment, 19 (21.8%) were on afatinib, 49 (56.3%) were on gefitinib,
and 19 (21.8%) were on erlotinib. The median progression-free survival (mPFS) of
these patients is as shown in the table. Of 20 patients (23.0%) who developed new
symptomatic brain metastases, one (5.0%) had new leptomeningeal metastases, three
(15.0%) had both new leptomeningeal metastases and solid brain metastases, and the
remaining 16 (80.0%) had new solid brain metastases only. New leptomeningeal meta-
stases occurred in one patient treated with afatinib and three patients treated with gefi-
tinib. Forty-nine patients (56.3%) were investigated for acquired T790M mutation
either by plasma biopsy or tissue biopsy or both. The prevalence of acquired T790M
mutation was 61.2%. There was no difference in the pattern of PD or prevalence of
acquired T790M mutation among patients treated with afatinib, gefitinib or erlotinib.
Conclusions: New leptomeningeal metastases were uncommon in patients receiving
first-line EGFR-TKI. The choice of first-line first- or second generation EGFR-TKI did
not influence the pattern of PD and prevalence of acquired T790M mutation. However,
patients receiving afatinib appeared to have longer mPFS than those on gefitinib or
erlotinib.
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Median PFS, months 11.0 13.1 10.9 7.8 0.479
New brain metastases, No. (%) Yes No 20 (23.0) 67 (77.0) 5 (26.3) 14 (73.7) 12 (24.5) 37 (75.5) 3 (15.8) 16 (84.2) 0.692
New solid brain lesion metastases, No (%) Yes No 19 (21.8) 68 (78.2) 4 (21.1) 15 (78.9) 12 (24.5) 37 (75.5) 3 (15.5) 16 (84.2) 0.735
New leptomeningeal metastases, No. (%) Yes No 4 (4.6) 83 (95.4) 1 (5.2) 18 (94.8) 3 (6.1) 46 (93.9) 0 19 (100) 0.550
No. of patients tested for acquired T790M mutation n¼ 49 n¼ 14 n¼ 27 n¼ 8 p-value
Acquired T790M mutation detected, No. (%) Yes No 30 (61.2) 19 (38.8) 9 (64.3) 5 (35.7) 16 (59.3) 11(40.7) 5 (62.5) 3 (37.5) 0.949
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